Praluent Injection Price and How to Obtain It
The price of Praluent (alirocumab) injections can vary significantly based on factors such as dosage, quantity, and insurance coverage. For individuals without insurance, a 30-day supply of Praluent can range from approximately $300 to over $500. However, prescription assistance programs and manufacturer coupons may be available to help reduce out-of-pocket costs [1].
What Factors Influence Praluent's Cost?
The cost of Praluent is influenced by several components of the pharmaceutical market. These include the drug's development and manufacturing expenses, research and clinical trial investments, and marketing efforts. Additionally, Praluent's pricing strategy is set by its manufacturer, Sanofi and Regeneron Pharmaceuticals, and is also subject to market competition and the reimbursement policies of various insurance providers [1].
Does Insurance Cover Praluent?
Many insurance plans provide coverage for Praluent, though the extent of this coverage can differ. Patients are advised to consult with their insurance provider to understand their specific benefits, including deductibles, copayments, and any required prior authorization for Praluent prescriptions [1].
Are There Savings Programs for Praluent?
Yes, Sanofi and Regeneron offer savings programs designed to lower the cost of Praluent for eligible patients. These programs often include copay cards or coupons that can significantly reduce the amount individuals pay for their medication. Information on these savings programs can typically be found on the official Praluent website or through discussions with a healthcare provider [1].
What Is Praluent Used For?
Praluent is a prescription medication used to treat adults with high cholesterol. It is prescribed for individuals with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lipid-lowering therapy beyond diet and maximally tolerated statin therapy. Praluent works by lowering low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol [2].
How Does Praluent Work?
Praluent belongs to a class of drugs called PCSK9 inhibitors. It is a monoclonal antibody that targets and inhibits the PCSK9 protein. This inhibition leads to an increase in the number of LDL receptors on the surface of liver cells, which in turn enhances the removal of LDL cholesterol from the bloodstream [2].
When Did Praluent's Patents Expire?
Understanding Praluent's patent landscape is crucial for anticipating market changes and the potential introduction of generic alternatives. Patents for drugs like Praluent are complex and can involve multiple filings covering various aspects of the drug, including its composition, method of use, and manufacturing processes [3].
DrugPatentWatch.com tracks patent expirations and can provide detailed information on the patent status of Praluent [3]. The expiration of these patents is a key factor in determining when biosimilar or generic versions might become available, potentially impacting the overall market price.
---
Sources:
[1] https://www.praluent.com/
[2] https://www.rxlist.com/praluent-drug.htm
[3] https://drugpatentwatch.com/